亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study

医学 淋巴血管侵犯 外科肿瘤学 危险系数 内科学 放化疗 食管鳞状细胞癌 倾向得分匹配 肿瘤科 腹部外科 食管癌 回顾性队列研究 比例危险模型 外科 胃肠病学 癌症 置信区间 转移
作者
Yoshinobu Yamamoto,Ryu Ishihara,Hirofumi Kawakubo,M. Nishikawa,Sachiko Yamamoto,Tomohiro Kadota,Seiichiro Abe,Masao Yoshida,Tsutomu Tanaka,Hiroaki Nagano,Hiroyoshi Nakanishi,Tetsuya Yoshizaki,Kotaro Waki,Akiko Takahashi,Yoshiyasu Kitagawa,Ken‐ichi Mizuno,Kenro Kawada,Yoshiyasu Kono,Chikatoshi Katada,Takashi Hashimoto,Yasuaki Nagami,Toshiyuki Yoshio,Toshio Shimokawa,Keiji Nihei,Kazuo Koyanagi,Ken Kato,Tomonori Yano,Manabu Muto,Yuko Kitagawa
出处
期刊:Journal of Gastroenterology [Springer Nature]
标识
DOI:10.1007/s00535-024-02188-7
摘要

Abstract Background Lymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered. Methods This was a multicenter, retrospective study conducted at 65 hospitals in Japan. The inclusion criteria were patients with ESCC who underwent ER between January 2006 and December 2015, with pT1a-muscularis mucosa (MM) with LVI or pT1b, with negative vertical margins, cN0M0, and who underwent surgery or CRT. A 1:1 propensity score-matched analysis was performed between two groups. The primary and secondary end points were overall survival (OS) and relapse-free survival (RFS). OS and RFS were also compared between two subgroups: low risk (pT1a-MM with LVI and pT1b without LVI) and high risk (pT1b with LVI) for metastatic recurrence. Results Among 472 patients, 160 patients were selected from each group. The OS and RFS did not differ between surgery and CRT groups (hazard ratio, 0.887; P = .635 and hazard ratio, 1.036; P = .876, respectively). Subgroup analysis showed that CRT had a better prognosis in the low-risk group, and conversely, surgery had a better prognosis in the high-risk group. But these were not significant. The high-risk CRT group had a significant worse prognosis than the low-risk CRT group. Conclusions In patients with noncurative ER for ESCC, surgery and CRT showed no difference in long-term outcomes. Indications for CRT in the high-risk group need further investigation because of poor prognosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
磨刀霍霍阿里嘎多完成签到 ,获得积分10
8秒前
要减肥的春天完成签到,获得积分10
12秒前
共享精神应助冷酷的鹏涛采纳,获得10
18秒前
uss完成签到,获得积分10
20秒前
阿布应助仁爱的念文采纳,获得10
29秒前
从来都不会放弃zr完成签到,获得积分10
37秒前
直率的雪巧完成签到,获得积分10
49秒前
科研通AI6应助inRe采纳,获得10
1分钟前
研友_VZG7GZ应助xuzb采纳,获得10
1分钟前
1分钟前
1分钟前
斯文败类应助SiboN采纳,获得10
1分钟前
CodeCraft应助科研通管家采纳,获得10
1分钟前
思源应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
2分钟前
冷酷的鹏涛完成签到,获得积分10
2分钟前
2分钟前
墨薄凉完成签到 ,获得积分10
2分钟前
轻松一曲应助inRe采纳,获得10
2分钟前
hlq完成签到 ,获得积分10
2分钟前
xuzb完成签到,获得积分10
3分钟前
3分钟前
龙龙冲发布了新的文献求助20
3分钟前
美满尔蓝完成签到,获得积分10
3分钟前
纪言七许完成签到 ,获得积分10
3分钟前
小马甲应助龙龙冲采纳,获得10
3分钟前
英勇的醉蓝完成签到,获得积分20
3分钟前
qinglongtsmc发布了新的文献求助10
3分钟前
ding应助英勇的醉蓝采纳,获得10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
null应助科研通管家采纳,获得10
3分钟前
inRe发布了新的文献求助10
4分钟前
4分钟前
4分钟前
4分钟前
SiboN发布了新的文献求助10
4分钟前
xuzb发布了新的文献求助10
4分钟前
qinglongtsmc完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Reproduction Third Edition 3000
《药学类医疗服务价格项目立项指南(征求意见稿)》 1000
花の香りの秘密―遺伝子情報から機能性まで 800
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
Chemistry and Biochemistry: Research Progress Vol. 7 430
Bone Marrow Immunohistochemistry 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5628172
求助须知:如何正确求助?哪些是违规求助? 4715898
关于积分的说明 14963806
捐赠科研通 4785879
什么是DOI,文献DOI怎么找? 2555413
邀请新用户注册赠送积分活动 1516720
关于科研通互助平台的介绍 1477252